CONFIDENTIALMulti-Product License Agreement • April 1st, 2019 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
= Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed AMENDMENT No. 9 To the MULTI- PRODUCT LICENCE AGREEMENT datedMulti-Product License Agreement • March 1st, 2022 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 9 (“Amendment No. 9”) to the Multi-Product License Agreement, dated 31 October 2014, and as amended by Amendment No. 1, dated 28 July 2015 , Amendment No. 2, dated 07 October 2015, Amendment No. 3, dated 26 April 2016, Amendment No. 4, dated 03 October 2017, Amendment No. 5, dated 16 March 2018, Amendment No. 6, dated 06 February 2019, Amendment 7, dated 22 December 2020 and Amendment 8, dated 10 February 2021 (collectively the “Agreement”) is made effective as of the last dates of signatures between the parties (the “Amendment No. 9 Effective Date”); and is
CONFIDENTIALMulti-Product License Agreement • March 15th, 2021 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 8 (“Amendment No.8”) to the Multi-Product License Agreement, dated 31 October 2014, and as amended by Amendment No. 1, dated 28 July 2015 , Amendment No. 2, dated 07 October 2015, Amendment No. 3, dated 26 April 2016, Amendment No. 4, dated 03 October 2017, Amendment No. 5, dated 16 March 2018, Amendment No. 6, dated 06 February 2019 and Amendment 7, dated 22 December 2020 (collectively the “Agreement”) is made effective as of the last dates of signatures between the parties (the “Amendment No. 8 Effective Date”); and is
MULTI-PRODUCT LICENCE AGREEMENTMulti-Product License Agreement • November 2nd, 2023 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 10 (“Amendment No. 10”) is made as of the last date of signature between the Parties (the “Amendment No. 10 Effective Date”)
AMENDMENT NO.3 to the Multi-Product License Agreement dated 22 August 2012 between LONZA SALES AG and ONCOMED PHARMACEUTICALS, INCMulti-Product License Agreement • November 2nd, 2017 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as "Lonza") and
ContractMulti-Product License Agreement • October 25th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractMulti-Product License Agreement • March 12th, 2015 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractMulti-Product License Agreement • November 5th, 2015 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
